Clinical Characteristics, Treatment Patterns, and Healthcare Resource Utilization of Patients Prescribed Aripiprazole Lauroxil Versus Oral Aripiprazole: A Retrospective Claims-Based Study

John M. Kane, MD,¹ Andrea B. Barthel, MS,² Chenxue Liang,² Zhengfan Wang,² Elizabeth S. Nagelhout,² Lauren N. Strand, PhD, MS,³ Michael J. Doane, PhD,³ Regina Grebla, PhD³

¹The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA; ²Genesis Research, Hoboken, NJ, USA; ³Alkermes, Inc., Waltham, MA, USA

INTRODUCTION

- Nonadherence to oral medication is a known challenge among some patients with schizophrenia¹
- Gaps in oral antipsychotic use are associated with an increased risk of hospitalization²
- Long-acting injectable (LAI) antipsychotics provide consistent medication exposure and are associated with greater adherence, lower discontinuation rates, and reduced acute healthcare resource utilization (HCRU) compared with oral antipsychotics³⁻⁶
- Aripiprazole lauroxil (AL) is an atypical LAI antipsychotic indicated for the treatment of adults with schizophrenia and is available with
- monthly, every-6-weeks, and every-2-months dosing options that can be paired with a separate 1-day initiation regimen^{7,8}
 In previous real-world studies of patients with schizophrenia, treatment initiation with AL was associated with significant reductions
- in the numbers of mental health–related inpatient (IP) admissions and emergency department (ED) visits^{9,10}

OBJECTIVE

• To compare demographic and clinical characteristics, treatment patterns, and HCRU among adults with schizophrenia initiating AL versus oral aripiprazole (OA)


METHODS

Data Source

- Administrative claims data from January 1, 2016, to June 30, 2022, for privately and publicly insured persons across the US obtained from the Merative[™] MarketScan[®] Research Databases Commercial Claims and Encounters (CCAE), Medicare Supplemental (MDCR), and Medicaid Multi-State (MDCD) databases were analyzed retrospectively
- The CCAE database includes approximately 62.9 million covered lives per year; the MDCR and MDCD databases represent
 2.6 million and 16.8 million lives (over 3 years), respectively

Study Design and Patient Selection

Figure 1. Study Design



^aPatients had to have ≥12 months of continuous enrollment before and ≥12 months of continuous enrollment after the index date; baseline medical history was based on the 12-month period before and inclusive of the index date. ^bI follow-up period from the index date (exclusive) to the date of disenrollment or end of study period allowed for a fixed 12 months of follow-up to assess treatment patterns and healthcare resource utilization. ^cDate of first aripiprazo lauroxil or oral aripiprazole claim on or after initial diagnosis date. ^dThe second of 2 claims (pharmacy or medical) was required to be within 6 months of the first claim.

Criteria for patient identification for this analysis are listed in Figure 2

Outcomes

- Demographics and baseline clinical characteristics by treatment group (AL or OA)
- Treatment patterns
- Discontinuation: a continuous gap of ≥60 days without a claim for the index prescription, beginning after the therapeutic window
 for AL or after the previous claim's days' supply for OA
- Persistence: the number of days from the index date to date of first discontinuation or end of the 1-year follow-up period, whichever occurred first
- Switching: the presence of a claim for antipsychotic medication other than that initiated at index within the 60-day maximum allowable gap from the date of discontinuation
- Proportion of days covered (PDC): calculated as number of available days of index therapy divided by 365
- Adherence: PDC ≥ 0.80
- HCRU outcomes
- Numbers of patients with all-cause and mental health—related IP admissions and outpatient (OP) and ED visits
 Utilization per patient per month (PPPM) for the outcomes listed above as well as all-cause OP pharmacy claims

Statistical Analysis

- Propensity score matching (using a 1:1 matching ratio) was used to balance the treatment groups on 23 measured covariates (eg, age, sex, index year, and baseline HCRU)
- Treatment patterns
- Persistence was compared between the matched AL and OA cohorts using a Cox proportional hazards model
 Adherence (PDC ≥ 0.80) was compared between the 2 matched cohorts using a logistic regression model
 The other treatment pattern outcomes were analyzed descriptively
- HCRU
- A logistic regression model was fitted to compare binary HCRU outcomes (occurrence of event, yes or no) between the 2 matched cohorts
- A 2-part modeling strategy combining logistic and Poisson regression models was used to compare visit counts PPPM for each cohort and all-cause drug claims PPPM, yielding the estimated rate ratio (RR); bootstrapping was used for generating the 95% CI


RESULTS

• The total sample size was 6599 patients (AL cohort, n=732 patients; unmatched OA cohort, n=5867) (Figure 2, Table 1)

Figure 2. Patient Identification^a

'Patients with ≥1 pharmacy claim during the 12-month baseline perioc

ADHD, attention-deficit/hyperactivity disorder; AL, aripiprazole lauroxil; CCI, Charlson Comorbidity Index; OA, oral aripiprazole



^aPatients were categorized into AL and OA cohorts using a hierarchical approach. If patients had ≥2 AL claims on or after the initial diagnosis date, they were classified in the AL cohort; otherwise, patients were classified in the OA cohort if they had ≥2 OA claims on or after the initial diagnosis date. ^bMaintaining patients with schizophrenia on treatment can be a clinical challenge. At least 2 claims were required to examine outcomes in the subset of patients across both treatment cohorts who may be more likely to benefit from treatment.


AL, aripiprazole lauroxil; ICD-10-CM, *International Classification of Diseases, Tenth Revision, Clinical Modification*; IP, inpatient; LAI, long-acting injectable; OA, oral aripiprazole; OP, outpatient.

• Optimal propensity score matching (standardized mean differences for all covariates <0.10) was achieved using a 1:1 matching ratio (matched OA cohort, n=732)

Table 1. Patient Demographics and Baseline Clinical Characteristics Before Propensity Score Matching

Characteristics	AL Cohort (n=732)	OA Cohort (n=5867)
Age at index, mean (SD), years	37.3 (13.4)	39.7 (13.9)
Female, n (%)	323 (44.1)	2941 (50.1)
Year of index, n (%)		
2017	91 (12.4)	992 (16.9)
2018	105 (14.3)	1098 (18.7)
2019	196 (26.8)	1452 (24.7)
2020	234 (32.0)	1503 (25.6)
2021	106 (14.5)	822 (14.0)
Payer type, n (%)		
Commercial	45 (6.1)	882 (15.0)
Medicaid	683 (93.3)	4959 (84.5)
Medicare Supplemental	4 (0.5)	26 (0.4)
CCI, mean (SD)	0.88 (1.4)	1.08 (1.8)
Treatment history (past 12 months), n (%)		
Typical oral antipsychotic	155 (21.2)	902 (15.4)
Atypical oral antipsychotic	627 (85.7)	3794 (64.7)
Oral aripiprazole	416 (56.8)	0
Mood stabilizer	386 (52.7)	3023 (51.5)
Antidepressant	494 (67.5)	4271 (72.8)
Anticholinergic	234 (32.0)	1703 (29.0)
Sedative/hypnotic	109 (14.9)	714 (12.2)
Antianxiety medication	325 (44.4)	2762 (47.1)
Stimulant/ADHD medication	197 (26.9)	1734 (29.6)

Figure 3. Index Prescription Dose



^aThree patients had an index dose of 675 mg AL_{NCD} (Initio), and their next AL claim had an unknown dose or was 675 mg. AL, aripiprazole lauroxil; AL_{NCD} , NanoCrystal Dispersion formulation of AL; OA, oral aripiprazole.

• In the AL cohort, more patients were adherent to their medication compared with those in the matched OA cohort, and medication persistence was longer (Table 2)

Table 2. Treatment Patterns Among Matched Patient Cohorts

12-Month follow-up treatment patterns	AL Cohort (n=732)	Propensity Score–Matched OA Cohort (n=732)		
Discontinuation, n (%) ^a	362 (49.5)	522 (71.4)		
Persistence, days, median (Q1, Q3) ^b	365.0 (154.0, 365.0)	153.0 (72.0, 365.0)		
HR (95% CI), <i>P</i> °	0.5 (0.44, 0	0.5 (0.44, 0.56), < 0.0001		
Switching, n (%) ^d	163 (22.3)	216 (29.4)		
To oral antipsychotic	135 (18.4)	183 (24.9)		
To LAI antipsychotic	28 (3.8)	33 (4.5)		
PDC, mean (SD) ^e	0.72 (0.27)	0.51 (0.22)		
Adherence (PDC ≥ 0.80), n (%)	369 (50.4)	176 (24.0)		
OR (95% CI), <i>P</i> ^c	3.22 (2.57, 4.02), <0.0001			

^aDiscontinuation was defined as a continuous gap of ≥60 days without a claim for the index prescription, beginning after the therapeutic window for AL or after the previous claim's days' supply for OA. ^bPersistence was defined as number of days the from index date to date of first discontinuation or end of the 1-year follow-up period, whichever occurred first. ^cReference = OA. ^dSwitching was defined as the presence of a claim for antipsychotic medication othe than that initiated at index within the 60-day maximum allowable gap period after the date of discontinuation. ^ePDC was calculated as number of available days of index therapy divided by 365.

AL, aripiprazole lauroxil; HR, hazard ratio; LAI, long-acting injectable; OA, oral aripiprazole; OR, odds ratio; PDC, proportion of days covered, Qn, quartile number.

- Fewer patients in the AL cohort had all-cause IP and ED visits versus the OA cohort; odds of having ≥1 mental health—related IP visit were also significantly lower for patients who initiated AL (Figure 4)
- Numbers of all-cause and mental health-related IP and ED visits PPPM were significantly lower for the AL cohort vs the matched OA cohort (Figure 5)
- OP utilization did not differ between the matched cohorts

Figure 4. All-Cause and Mental Health–Related IP, OP, and ED Visits

HCRU Event	AL, n (%) (N=732)	Matched OA, n (%) (N=732)		ORa	95% CI	P
All-Cause			 			
≥1 IP visit	253 (34.6)	302 (41.3)	├──■	0.75	(0.61, 0.93)	0.0079
≥1 ED visit	427 (58.3)	470 (64.2)		0.78	(0.63, 0.97)	0.0222
≥1 OP visit	727 (99.3)	731 (99.8)		− 0.27	(0.04, 1.80)	0.1741
Mental Health-Relat	ed					
≥1 IP visit	232 (31.7)	280 (38.3)		0.75	(0.60, 0.93)	0.0082
≥1 ED visit	282 (38.5)	314 (42.9)		0.83	(0.68, 1.03)	0.0888
≥1 OP visit	695 (94.9)	705 (96.2)		0.73	(0.44, 1.21)	0.2280
			0.0 0.5 1.0 1.5 OR (95% CI) for AL vs OA	2.0		

^aReference = OA.

AL, aripiprazole lauroxil; ED, emergency department; HCRU, healthcare resource utilization; IP, inpatient; OA, oral aripiprazole; OP, outpatient; OR, odds ratio.

Figure 5. Numbers of All-Cause and Mental Health–Related IP, OP, and ED Visits, PPPM

HCRU Event	AL, mean (SD) (N=732)	Matched OA, mean (SD) (N=732)		RR ^a	95% CI ^b
All-Cause					
Number of IP visits PPPM	0.08 (0.18)	0.09 (0.12)	├──	0.83	(0.70, 0.97)
Number of ED visits PPPM	0.28 (0.57)	0.34 (0.49)	<u> </u>	0.85	(0.72, 0.98)
Number of OP visits PPPM	7.03 (8.30)	7.50 (6.87)		0.94	(0.86, 1.03)
Mental Health-Related					
Number of IP visits PPPM	0.07 (0.17)	0.08 (0.11)	├──■	0.84	(0.70, 0.98)
Number of ED visits PPPM	0.12 (0.29)	0.15 (0.26)		0.78	(0.65, 0.93)
Number of OP visits PPPM	3.34 (4.23)	3.62 (3.88)		0.93	(0.84, 1.03)

0.0 0.5 1.0 1.5

Favors AL Favors OA

^aReference = OA. ^bThe bootstrapping model conducted to compare counts PPPM between cohorts did not produce *P* values; CIs were reported for hypothesis testing.

AL, aripiprazole lauroxil; ED, emergency department; HCRU, healthcare resource utilization; IP, outpatient; OA, oral aripiprazole; OP, outpatient; PPPM, per patient per month; RR, rate ratio.

LIMITATIONS

- Requiring ≥12 months of continuous enrollment before and after the index date may have limited sample size
- Requiring 2 claims of AL and OA may have increased estimates of adherence and persistence; however, the requirement was the same for both cohorts
- Claims related to schizophrenia and its treatment may not have been accurately or completely captured, which could have led to inaccurate reports of treatment patterns and underestimation of HCRU

CONCLUSIONS

- In this real-world study of patients with schizophrenia, patients initiating AL were more likely to be adherent to treatment and had longer medication persistence compared with patients initiating OA
- AL was associated with significantly reduced odds of all-cause IP and ED visits and mental health related IP visits versus OA
- Numbers of visits to OP settings were similar between AL and OA
- All-cause and mental health—related IP admissions and ED visits PPPM were also significantly reduced among patients initiating AL versus OA
- Future investigations may explore whether the improved adherence and persistence and concurrent reductions in acute HCRU associated with use of LAI AL versus OA translate into lower rates of relapse and reduced physical, psychosocial, and economic burden experienced by patients with schizophrenia

REFERENCES

1. Greene M, et al. *J Med Econ.* 2018;21(2):127-34. DOI: 10.1080/13696998.2017.1379412. 2. Weiden PJ, et al. *Psychiatr Serv.* 2004;55(8):886-91. DOI: 10.1176/appi.ps.55.8.886. 3. Milz R, et al. *Neuropsychiatr Dis Treat.* 2023;19:531-45. DOI: 10.2147/ndt.s395383. 4. Romagnoli A, et al. *Curr Clin Pharmacol.* 2021;16(1):115-22. DOI: 10.2174/1574884715666200309121932. 5. Lin D, et al. *CNS Drugs.* 2021;35(5):469-81. DOI: 10.1007/s40263-021-00815-y. 6. Shah A, et al. *Adv Ther.* 2018;35(11):1994-2014. DOI: 10.1007/s12325-018-0786-x. 7. Aristada [package insert]. Waltham, MA: Alkermes, Inc.; 2023. 8. Aristada Initio [package insert]. Waltham, MA: Alkermes, Inc.; 2023. 9. Lauriello J, et al. *CNS Drugs.* 2021;35(10):1123-35. DOI: 10.1007/s40263-021-00849-2. 10. Strand LN, et al. Presented at: Annual Meeting of the American Association of Psychiatric Pharmacists; April 7-10, 2024; Orlando, FL.

Disclosure information, acknowledgments, and copies of this poster can be obtained through this QR (Quick Response) code. These materials are for personal use only and may not be reproduced without permission of Alkermes. For permission, contact USMedInfo@Alkermes.com



Clinical Characteristics, Treatment Patterns, and Healthcare Resource Utilization of Patients Prescribed Aripiprazole Lauroxil Versus Oral Aripiprazole: A Retrospective Claims-Based Study

John M. Kane, MD,¹ Andrea B. Barthel, MS,² Chenxue Liang,² Zhengfan Wang,² Elizabeth S. Nagelhout,² Lauren N. Strand, PhD, MS,³ Michael J. Doane, PhD,³ Regina Grebla, PhD³

¹The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA; ²Genesis Research, Hoboken, NJ, USA; ³Alkermes, Inc., Waltham, MA, USA

AUTHOR DISCLOSURES

JMK has been a consultant for or received honoraria from Alkermes, Boehringer Ingelheim, Click Therapeutics, Intra-Cellular Therapies, Janssen, Johnson & Johnson, Karuna, LB Pharmaceuticals, Lundbeck, Lyndra, Merck, Neurocrine Biosciences, Newron, Otsuka, Pierre Fabre, Reviva, Roche, Saladax, Sunovion, Takeda, and Teva; has received grant support from Janssen, Lundbeck, and Otsuka; and is a shareholder of LB Pharmaceuticals and Vanguard Research Group

ABB, CL, ZW, and ESN have nothing to disclose

LNS, MJD, and RG are or were employees of Alkermes, Inc., and may own stock/options in the company

ACKNOWLEDGMENTS

This study was sponsored by Alkermes, Inc. (Waltham, MA, USA). Medical writing and editorial support were provided by Peloton Advantage, LLC, an OPEN Health company, and funded by Alkermes, Inc.